Introduction: Steven-Johnson syndrome (SJS) is a serious mucocutaneous reaction, characterized by fever, influenza-like symptoms and followed by dermatological manifestations. Capecitabine is an oral fluoropyrimidine carbamate analogue of 5-Fluorouracil (5-FU). It is widely accepted for many malignancies because of its better safety profile and tolerability. Hand-foot syndrome is the common dermatological toxicity associated with Capecitabine and SJS is the rarest manifestation. We report a case of Capecitabine induced SJS in a 70 years old male patient with metastatic carcinoma pancreas. He was treated with intravenous Gemcitabine and Carboplatin initially and then switched to oral therapy with Capecitabine 1000 mg twice daily. After ten days of treatment with Capecitabine, he developed vomiting, mucositis, hyperpigmentation, itching and scrotal mucosal peeling. The clinical status of the patient was suggestive of SJS, which was confirmed by dermatologic consultation. According to Naranjo, WHO-UMC, and Hartwig's scale, the reaction was found to be probable and severe. Pharmacological as well as supportive care measures were provided, but the condition progressively worsened, and the patient was deceased.
Conclusion: Capecitabine can cause severe hypersensitivity reactions which can be dangerous and life-threatening. Health care providers must be aware of all rare adverse effects, including SJS. Clinicians and clinical pharmacists should educate and counsel the patients regarding the likely adverse effects of their chemo drugs because the early identification of toxic symptoms is crucial to reduce further complications to the patient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10781552211027945 | DOI Listing |
Cancer J
January 2025
From the Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Purpose: Chemoradiation-induced lymphopenia is common and associated with poorer survival in multiple solid malignancies. However, the association between chemoradiation-related lymphopenia and survival outcomes in rectal cancer is yet unclear. The objective of this study was to evaluate the prognostic impact of lymphopenia and its predictors in patients with rectal cancer undergoing neoadjuvant chemoradiation.
View Article and Find Full Text PDFBMC Cancer
January 2025
Department of Pharmacy, Hainan Cancer Hospital, Haikou, Hainan, China.
Background: To identify the factors influencing pyrotinib-induced severe diarrhea and to establish a risk prediction nomogram model.
Methods: The clinical data of 226 patients received pyrotinib from two medical institutions from January 2019 to December 2023 were analysed retrospectively. A training set was made up of 167 patients from Hainan Cancer Hospital, and the external validation set was made up of 59 patients from Hainan West Central Hospital.
BMJ Case Rep
January 2025
Internal Medicine, Carolinas Medical Center, Charlotte, North Carolina, USA.
Capecitabine is a widely used drug for cancer treatment. Capecitabine is a derivative of 5-fluorouracil (5-FU). A known complication of 5-FU is hyperammonaemia which can cause encephalopathy.
View Article and Find Full Text PDFInt Cancer Conf J
January 2025
Department of Otolaryngology-Head and Neck Surgery, Kagawa Rosai Hospital, Kagawa, Japan.
First-bite syndrome (FBS) is manifested as acute and severe pain in the parotid region occurring at the first bite of a meal. While most cases of FBS arise after surgeries involving the deep lobe of the parotid gland, chemotherapy-induced FBS is extremely rare. Some adverse effects of oxaliplatin resemble FBS, suggesting it may be under-recognized.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
November 2024
Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Background: The management of capecitabine-related hand-foot syndrome (HFS) is critical to avoid progression of the syndrome through early detection and early response; management of HFS involves joint medication management by physicians and pharmacists (hospital and community pharmacists). This study aimed to evaluate the effectiveness of collaborative medication management in cancer patients with HFS by comparing its effectiveness with the traditional response using monitoring reports from community pharmacists.
Patients And Methods: Medical records of 120 breast cancer patients who received capecitabine therapy between September 2017 and August 2023 were retrospectively reviewed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!